Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been given a consensus rating of "Buy" by the eight research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $13.20.

A number of equities research analysts have recently commented on IMUX shares. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. Wall Street Zen cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. D. Boral Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, April 30th. William Blair reiterated an "outperform" rating on shares of Immunic in a report on Friday, May 16th. Finally, B. Riley reiterated a "buy" rating and issued a $6.00 price objective on shares of Immunic in a report on Wednesday, April 16th.

Immunic Stock Down 0.2%

Shares of NASDAQ:IMUX traded down $0.00 during trading on Friday, reaching $0.92. 79,696 shares of the company's stock traded hands, compared to its average volume of 715,193. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11. The firm has a market cap of $87.96 million, a PE ratio of -0.75 and a beta of 1.73. The company has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $1.08.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). On average, equities research analysts forecast that Immunic will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. purchased a new stake in shares of Immunic during the 4th quarter valued at approximately $37,000. HB Wealth Management LLC purchased a new stake in shares of Immunic during the 4th quarter valued at approximately $81,000. Barclays PLC purchased a new stake in shares of Immunic during the 4th quarter valued at approximately $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after buying an additional 96,894 shares during the period. Finally, Bridgeway Capital Management LLC raised its position in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after buying an additional 22,200 shares during the period. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.